Phaseline

Companies › Genrix (Shanghai) Biopharmaceutical

Genrix (Shanghai) Biopharmaceutical: clinical trials, targets and expected readouts

4 active drug programs in 9 registered trials: 3 Phase 3, 3 Phase 2, 3 Phase 1; Immunology, Oncology, Other, Respiratory; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
GR1803 injection–Phase 3Multiple Myeloma; Multiple Myleoma; Systemic Lupus ErthematosusMay 2027
GR1802
anti-IL4Rα monoclonal antibody
IL4RPhase 3Allergic Rhinitis, Seasonal; Chronic Rhinosinusitis With Nasal Polyps; Allergic Rhinitis–
GR2303 injection–Phase 1Health Adult SubjectsDec 2026
GR1603
Anti-IFNAR1 monoclonal antibody
IFNAR1Phase 1Lupus Erythematosus, SystemicJun 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06315426GR1802Phase 2Allergic RhinitisImmunologyMay 2025
NCT07154342GR1802Phase 3Allergic Rhinitis, SeasonalImmunologyApr 2026
NCT06516302GR1802Phase 3Chronic Rhinosinusitis With Nasal PolypsRespiratoryJun 2026
NCT07199270GR2303 injectionPhase 1Health Adult SubjectsOtherDec 2026
NCT06566547GR1803 injectionPhase 2Multiple MyelomaOncologyMay 2027
NCT07348055GR1803 injectionPhase 1Systemic Lupus ErthematosusImmunologyJun 2027
NCT06952075GR1803 injectionPhase 2Multiple MyleomaOncologyJul 2027
NCT06015230GR1603Phase 1Lupus Erythematosus, SystemicImmunologyJun 2028
NCT07452198GR1803 injectionPhase 3Multiple MyelomaOncologyMar 2029

Targets

IFNAR1 (1) IL4R (1)

Companies with the same targets

Diakonos Oncology PharmaEssentia BriaCell Therapeutics AstraZeneca Brii Biosciences Xiamen Amoytop Biotech Biogen Apogee Therapeutics Guangdong Hengrui Pharmaceutical Sanofi

Companies built like this

Anterogen Keymed Biosciences Co.Ltd Apogee Therapeutics Direct Biologics Inmunotek

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.